Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

Sponsor
Vejle Hospital
Study ID
NCT00792363
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Irinotecan — DRUG
    350 mg/m2 intravenously on day 1 every 3 weeks
  • Panitumumab — DRUG
    9 mg/kg intravenously on day 1 every 3 weeks

Study Details

The purpose of this study is to investigate the effect and the side effect profile of irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with metastatic colorectal cancer without KRAS mutations.

Key Dates

Start date
Nov 30, 2008
Status verified
Jun 2012
Primary completion
Dec 31, 2010
Completion
Aug 31, 2011

Study Design

Enrollment
32 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Primary Outcome Measure

Response Rate [ Time Frame: Every 9 weeks. Up to 6 months ]

Related Studies